B2B GU Cancers Triad 2021 - Experts’ Highlights Discussion: Renal Cell Carcinoma
SIU Academy®. Faculty / Presenter(s) . 05/21/21; 321262 Topic: Treatment
 Faculty / Presenter(s)
Faculty / Presenter(s)
About this activity
With the advent of new data on targeted therapies, immunotherapies, and novel combinations the treatment of RCC is in the midst of rapid progression. Multiple recently completed and ongoing preclinical and clinical studies are demonstrating incrementally improved outcomes. With these advances, there is an urgent need in the urological community to stay up to date with current evidence and guidelines and apply this knowledge to improve the outcomes for patients with RCC.

This Expert Highlights session summarizes the key points that were discussed during the B2B session on RCC. The faculty also discusses the management of patients who have RCC and who have tested positive for COVID-19 in order to provide guidance to the urological community on how to best incorporate these therapies into practice within a multidisciplinary setting, including how these treatments are adapted in the presence of COVID-19 infection.

Faculty
Moderator
Laurence Albigès, MD, PhD
Head, Genitourinary Unit
Gustave Roussy Institute
France

Axel Bex, MD, PhD
Professor of Urology
UCL Division of Surgery and Interventional Science
United Kingdom

Tian Zhang, MD, MHS
Associate Professor of Medicine
Duke Cancer Institute
United States




This educational activity is supported by SIU Corporate Sponsor Bristol Myers Squibb​.  

 

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies